Utah Dentist Loses Drug License Over Silent Bureaucracy
Published Date: 3/27/2025
Notice
Summary
Thomas Andr'e Endicott, a dentist from Utah, lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t legally prescribe or manage certain drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dentist
Thomas Andr'e Endicott, D.D.S., had his DEA Certificate of Registration No. FE3865029 revoked effective April 28, 2025 because his Utah dental license and Utah controlled-substance license were revoked on February 22, 2024. As a result, he cannot legally possess, prescribe, dispense, or otherwise handle controlled substances under his DEA registration.
Pending Renewal and New Registrations Denied
The DEA also denied any pending applications by Thomas Andr'e Endicott to renew or modify Certificate No. FE3865029 and denied any other pending application for additional registration in Utah, effective April 28, 2025. Those denials prevent him from restoring or adding DEA registration in Utah while the Order stands.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-05162 — Submission for Review: Verification of Who Is Getting Payments, RI 38-107 and RI 38-147
The Office of Personnel Management is bringing back a form that helps double-check who’s actually getting federal retirement payments. This affects retirees and federal agencies, making sure payments go to the right people without delays or mistakes. If you’re involved, keep an eye out for the chance to comment and help improve the process soon!
Next: 2025-05164 — Joely Keen, A.P.R.N.; Decision and Order
Joely Keen, a nurse practitioner from Texas, lost her DEA registration because she no longer has the legal right to handle controlled substances in Texas. This means she can’t prescribe or manage certain medications anymore. The decision is final, effective immediately, and impacts her ability to work with controlled drugs, with no money penalties mentioned.